Rituximab for autoimmune retinopathy: Results of a Phase I/II clinical trial.

ABSTRACT:

Purpose

This prospective study evaluates whether rituximab is a safe and potentially effective treatment for nonparaneoplastic autoimmune retinopathy (npAIR).

Materials and methods

Five npAIR patients were enrolled in a Phase I/II, prospective, nonrandomized, open-label, single-center study. All patients received a cycle of 1000 mg intravenous rituximab at weeks 0 and 2, with a second cycle of rituximab 6 to 9 months later. Clinical evaluation was performed at baseline, 6 and 12 weeks after each rituximab cycle, and then every 3 months for a total duration of 18 months. The primary outcome for this study was treatment success based on visual field and full-field electroretinography at 6 months. The secondary outcomes included treatment success at months 12 and 18, drug-relat

SUBMITTER: Armbrust KR 

PROVIDER: S-EPMC7971443 | biostudies-literature | 2021 Jan-Mar

REPOSITORIES: biostudies-literature